FDA approves Lucentis (Genentech) for treatment of Diabetic Macular Edema - 11-Aug-2012

The FDA on 10 August 2012 approved Lucentis (ranibizumab injection) from Genentech for the treatment of Diabetic Macular Edema (DME), a sight-threatening eye disease that occurs in people with diabetes. An injection of the drug is administered once a month by a health care professional. Lucentis is intended to be used along with good diabetic blood sugar control. DME is a condition in which fluid leaks into the macula, the center part of the retina where sharp, straight-forward vision occurs. The fluid makes the macula swell, causing vision to blur.